



Documentation of the Evidence leading to the final SSI Guideline and declaration of author's conflict of interest

1. Selection process for Swiss or International Guidelines

1.1. What guidelines were considered for the selection

Year of publication	Name of Organization	Link to pdf or PMID	Swiss / Intl
2015 (2018 update)	BASHH	https://www.bashhguidelines.org/current-guidelines/urethritis-and-cervicitis/chlamydia-2015/	Intl (UK)
2015	IUSTI	https://www.iusti.org	Intl (Europe)
2015	CDC	https://www.cdc.gov/std/chlamydia/default.htm	Intl (US)

Comment: *(e.g. if no reference guideline could be found)*

Separate excel file with all the guidelines initially considered for the selection is available. The guidelines from BASHH, IUSTI and CDC were then looked at in more detail.

1.2. Final selection of the reference Guideline

The following guideline was considered as the reference* guideline for the SSI:

Name of Organization / Guideline / PMID:

BASHH, 2015 UK national guideline for the management of infection with Chlamydia Trachomatis; including the 2018 update

.....

Date of decision: 25.10.2019

**In special settings, an additional guideline (e.g. pediatric) can be added as a reference guideline:*

Guideline: IUSTI, 2015 European guideline on the management of Chlamydia trachomatis infections

Remarks *(e.g. short comment on the rationale for the decision)*

BASHH is the most recently updated guideline, has a transparent policy for the development and assessment of guidelines (i.e. using GRADE). Information on financing of the guideline is also available.
BASHH guideline on Chlamydia does not include recommendations on LGV treatment. This information was included from the IUSTI guideline.

2. Description of specific issues for Swiss guidelines

Please indicate which part of the guideline needs to be amended for the use in Switzerland. Enlarge table as needed. Try to *limit description of amendments to one page*.

Topic (with page-nr)	Describe the change for the Swiss Guideline	Rationale for the change
Indication for testing	Indications for testing not covered in the BASHH guideline, therefore we kept the indications as in the previous version of the SSI Chlamydia guideline	We considered outlining indications for testing as a guideline for practitioners to be important
LGV therapy	LGV therapy recommendations are from the IUSTI guidelines as it is not included in the BASHH guideline	As the guideline is supposed to include LGV, we also wanted to include the therapy recommendations

Date of final agreement within the expert group for these changes: **06/03/2020**

3. Declaration of author's conflict of interest

The authors mentioned above declare the following conflicts of interest:

Julia Notter: no conflict of interest
Regina Kulier: no conflict of interest to declare

Date	Author	Name of Guideline doc
22.04.2020	Julia Notter	Chlamydia (C. trachomatis) / LGV SOP Chlamydia_09.03.2020.docx